

Herantis Pharma appoints Dr. Charlotte Videbæk Vice President Clinical Development

Herantis Pharma Plc

Company release 21 Mar 2022 at 09:00 am EET

Herantis Pharma Plc (“Herantis”), an innovative biotech company developing new disease modifying therapies for Parkinson’s disease, today announced the appointment of Charlotte Videbæk, MD, as Vice President Clinical Development and member of the management team, effective 1st of April 2022.

Dr. Videbæk is a board-certified neurologist from Copenhagen with a track record from international pharmaceutical companies developing therapies for neurodegenerative diseases, including Parkinson’s disease. She has worked at Novartis and Roche in Basel prior to joining Lundbeck in Copenhagen in various positions including VP Corporate Project Management R&D. Lately she has worked with earlier stage companies and focused on entrepreneurship.

“Charlotte’s education and extensive experience with developing therapies for neurodegenerative disorders make her an ideal fit to Herantis as our lead product HER-096 is entering the clinic,” said Frans Wuite, interim CEO of Herantis.

“Herantis has a truly unique, potentially disease modifying therapy for neurodegenerative disorders. I am thrilled to join Herantis at this exciting time, when the company is preparing to demonstrate that its lead product HER-096 can safely be given in man and that it can reach the brain upon subcutaneous administration. This would be a major milestone in the development of pharmaceuticals for neurodegenerative disorders,” commented Dr. Videbæk.

For more information, please contact:

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: ir@herantis.com

Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400

Company website: www.herantis.com

About Herantis Pharma Plc

Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s Disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic version of the active parent rhCDNF protein. It combines the compelling mechanism of action of the rhCDNF protein with the ability to be delivered to the brain via subcutaneous administration.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.